argenx
As of the edition of 20 October 2026, argenx runs 12 drugs, 1 of them marketed; it is on route A at 1 target and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 4 company names in this family.
- Forte Biosciences, Inc.: acquired in 2026; successor ARGEN-X N.V.
- Tocagen Inc.: acquired in 2026; successor ARGEN-X N.V.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 6 |
| Went quiet | 1 |
| Stopped | 2 |
| Status not established | 2 |
| Total | 12 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Efgartigimod alfa | Ends 2033 (computed from the first US licence) | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 1 target.
All 2 rows on route A or B
In the product2 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 2 targets where argenx needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Immune system: 39 trials led
- Nervous system: 30 trials led
- Cancer: 20 trials led